Table 5.

Linear regression model predicting eGFR changes (in milliliters per minute) in patients with stage 3 CKD (n=56) over the study period

Predictors of eGFR ChangesUnivariate ModelMultivariable Model
β (95% CI)P Valueβ (95% CI)P Value
Age, per 10 yr−0.06 (−2.8 to 2.7)0.970.81 (−1.9 to 3.5)0.56
Sex, men versus women1.6 (−4.2 to 7.4)0.58−0.27 (−6.2 to 5.6)0.93
Race, white versus nonwhite2.6 (−2.6 to 7.9)0.320.54 (−4.7 to 5.8)0.84
Diabetes versus nondiabetic−6.9 (−11 to −2.1)<0.01−8.0 (−13 to −2.7)0.004
Cirrhosis versus noncirrhotic−1.1 (−6.4 to 4.3)0.69−0.74 (−6.3 to 4.8)0.79
Hypertension versus normotensive−3.9 (−11 to 3.3)0.29−3.3 (−10.7 to 4.1)0.37
Baseline eGFR, per 10-ml/min increase in eGFR−0.05 (−3.1 to 3.0)0.97−1.5 (−4.8 to 1.7)0.34
Achieving sustained virologic response6.4 (−2.5 to 15.2)0.159.3 (0.44 to 18)0.04
  • Model constructed to predict change in eGFR in milliliters per minute from baseline to 6-month follow-up period. Post-treatment follow-up eGFR is missing from n=2 patients with baseline eGFR ≥60 ml/min per 1.73 m2 and n=1 patient with baseline eGFR <60 ml/min per 1.73 m2. 95% CI, 95% confidence interval.